<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F8C26247-C0F4-48D4-B1FC-EC2022D9F3B1"><gtr:id>F8C26247-C0F4-48D4-B1FC-EC2022D9F3B1</gtr:id><gtr:name>University of North Carolina Chapel Hill</gtr:name><gtr:address><gtr:line4>Chapel Hill</gtr:line4><gtr:line5>NC 27599-7431</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D739677A-6514-46E5-821F-22EEA573D62A"><gtr:id>D739677A-6514-46E5-821F-22EEA573D62A</gtr:id><gtr:name>University of Ghent</gtr:name><gtr:address><gtr:line1>Rectorate Building</gtr:line1><gtr:line2>Sint-Pietersnieuwstraat 25</gtr:line2><gtr:line3>Krijgslaan</gtr:line3><gtr:line4>Ghent</gtr:line4><gtr:line5>B-9000</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/49C44558-A75A-448F-9BF7-3F947FA67EB7"><gtr:id>49C44558-A75A-448F-9BF7-3F947FA67EB7</gtr:id><gtr:name>Technical University of Munich</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:department>Basic Medical Sciences</gtr:department><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F8C26247-C0F4-48D4-B1FC-EC2022D9F3B1"><gtr:id>F8C26247-C0F4-48D4-B1FC-EC2022D9F3B1</gtr:id><gtr:name>University of North Carolina Chapel Hill</gtr:name><gtr:address><gtr:line4>Chapel Hill</gtr:line4><gtr:line5>NC 27599-7431</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D739677A-6514-46E5-821F-22EEA573D62A"><gtr:id>D739677A-6514-46E5-821F-22EEA573D62A</gtr:id><gtr:name>University of Ghent</gtr:name><gtr:address><gtr:line1>Rectorate Building</gtr:line1><gtr:line2>Sint-Pietersnieuwstraat 25</gtr:line2><gtr:line3>Krijgslaan</gtr:line3><gtr:line4>Ghent</gtr:line4><gtr:line5>B-9000</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/49C44558-A75A-448F-9BF7-3F947FA67EB7"><gtr:id>49C44558-A75A-448F-9BF7-3F947FA67EB7</gtr:id><gtr:name>Technical University of Munich</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1E0F9F8C-1621-4F93-850F-2DC45C53D01D"><gtr:id>1E0F9F8C-1621-4F93-850F-2DC45C53D01D</gtr:id><gtr:firstName>Emma H</gtr:firstName><gtr:surname>Baker</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/5CD6733B-918F-41B4-93E8-7148B5A7C51F"><gtr:id>5CD6733B-918F-41B4-93E8-7148B5A7C51F</gtr:id><gtr:firstName>James</gtr:firstName><gtr:otherNames>Peter</gtr:otherNames><gtr:surname>Garnett</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7121308E-C650-4C72-85EE-DD0D177F6E43"><gtr:id>7121308E-C650-4C72-85EE-DD0D177F6E43</gtr:id><gtr:firstName>Deborah</gtr:firstName><gtr:surname>Baines</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FK012770%2F1"><gtr:id>4608E295-3943-4007-92FD-E2DCCD78DDC6</gtr:id><gtr:title>MICA: Evaluation of anti diabetic drugs in the treatment of respiratory disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K012770/1</gtr:grantReference><gtr:abstractText>The airways of the lung are lined with a thin layer of fluid (airway surface liquid, ASL) which is important for lung defence against infection. To optimise its function, the volume and composition of ASL are tightly regulated by the surface cells of the airway (epithelium). We have shown that the concentration of glucose (sugar) in ASL is normally much lower than that of blood. Our evidence indicates that this serves as a protective mechanism as glucose is a growth substrate for many organisms including infectious microbes. However, glucose concentration in ASL increases when the airways are inflamed, when blood glucose concentration is raised (hyperglycaemia, associated with diabetes or severe illness) and, more potently, when inflammation and hyperglycaemia are both present. This makes the airway more susceptible to infection particularly with pathogens such as methicillin resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. 

We have developed a cell model of human airway epithelium to understand how glucose concentration in ASL is regulated. We have shown that glucose applied to the basolateral (blood) side can get across the epithelium into the ASL. Normally the movement of glucose between the epithelial cells is restricted. However, when the epithelium becomes inflamed, it becomes leakier allowing glucose to pass across it more easily. If this is coupled with increased glucose concentration on the basolateral side (as in diabetes), even more glucose gets across. In this situation, we showed that the growth of bacteria in ASL was increased. In an exciting new development, we prevented the growth of bacteria by treating the epithelium with metformin (a drug already in clinical use). Metformin predominantly acted to prevent glucose getting into ASL and supporting bacterial growth. This could potentially provide a new therapeutic route for treatment of lung disease particularly in the light of increased resistance of bacteria to antibiotic therapy.
 
It is difficult to investigate how inflammation and diabetes increase glucose in ASL in the lungs of human subjects. Therefore, we will use our cell model and animal models of human lung disease to gain an understanding of how this occurs. We will investigate whether metformin can reduce glucose concentrations in ASL and suppress respiratory infection. We will also investigate whether other drugs that are predicted to reduce glucose movement into ASL will have a similar effect. In addition, we will test whether new drugs that are being developed to reduce blood sugar levels in diabetes have an additive beneficial effect. This project will increase our understanding of how glucose is increased in ASL in lung disease and when blood sugar levels are raised and how these two events promote infection. It will also tell us whether metformin or other drugs that reduce glucose movement across the epithelium or reduce blood glucose could be used to treat patients with these conditions. This could have important economic and social impact particularly in wealthy countries where the ageing population is expanding, chronic illness is more prevalent and the incidence of diabetes is increasing.</gtr:abstractText><gtr:technicalSummary>The respiratory tract is lined with a thin layer of fluid (airway surface liquid, ASL), which is important for lung defence against infection. Glucose concentrations in ASL are normally 12x lower than that of blood. However, they are raised in people during airway inflammation, hyperglycaemia and, more potently, when both are present, making the airway more susceptible to infection from pathogens such as methicillin-resistant S.aureus and P.aeruginosa. 

We have shown in airway epithelial cells in vitro that, under normal conditions, glucose diffuses from blood into ASL but accumulation is limited by the permeability of the epithelium, blood glucose concentration, glucose uptake into the epithelial cell via GLUT transporters and its metabolism. Inflammation increased transepithelial permeability to glucose and elevated glucose in ASL. In addition, increasing basolateral glucose concentration increased glucose in ASL and promoted the growth of S.aureus on the apical surface of lung epithelial cells. In vitro, pre-treatment of airway epithelia with metformin (a drug used in the treatment of type II diabetes) reduced epithelial permeability to glucose and prevented the apical growth of S. aureus. Metformin had no direct effect on bacterial growth or on basolateral glucose concentration.

This project will investigate how lung glucose homeostasis is modified by inflammation and hyperglycaemia in vitro and in vivo. It will identify whether metformin inhibits glucose accumulation in ASL and limits the growth of respiratory pathogens in vivo. It will also investigate the therapeutic effect of other drugs which are reported to reduce epithelial permeability or reduce blood glucose concentrations. e.g. azithromycin, glucokinase activators and SGLT2 inhibitors. The outcomes of this project will determine whether these drugs have potential therapeutic benefit in the prevention and treatment of respiratory infection and chronic pulmonary disease.</gtr:technicalSummary><gtr:potentialImpactText>This project has potential to impact the public sector, commercial private sector and the wider public. We have identified a drug that has the potential to treat epithelial disease and reduce infection that is distinct from current antibiotic and steroid therapies therefore opening up new possibilities for academic and pharmaceutical research in the short term. Investigation of how this drug works in both in vitro and in vivo systems will add to understanding of the function of epithelial tissues and aid identification of potential new targets for drug development for respiratory disease. This project will therefore directly impact scientists working in epithelia, inflammatory disease, infection and immunity and diabetes. 
The main output of this study will be new insights into glucose homeostasis in airway epithelium and its role in preventing infection. As part of this study we will characterise the effects of hyperglycaemia on glucose homeostasis in in vitro and in vivo models of airway epithelial disease. We will use bacterial co-culture/infection techniques to investigate the effect of hyperglycaemia on the growth of respiratory pathogens. The in vitro model we have developed will provide a useful tool for initial drug screening in development of non-antibiotic drugs to prevent lung infection and meets the principles of the 3Rs (Replacement, Refinement and Reduction). We are working with Astra Zeneca to utilize their models of inflammatory lung disease to translate our in vitro findings. They will also provide drugs have been developed but not yet fully available to test in these systems. Their involvement will promote development and translation and therefore enhance impact in this area. 
In the long term, we anticipate that understanding of the normal mechanisms that regulate glucose concentrations in the healthy airway, how factors associated with chronic disease and diabetes (prevalent in an ageing population) alter epithelial function and glucose homeostasis, together with the identification of drugs that prevent these effects, will ultimately benefit human and animal health with social and economic impact. Metformin is a drug already in clinical use with very few side effects. Understanding its action on epithelia and how this inhibits glucose flux and the growth of common pathogens such as S. aureus and Ps. aeruginosa provides a new and novel therapeutic mechanism and adds to the known activities of this drug. Data from this study will also add to the known activities of the other drugs studied. We anticipate that this knowledge will facilitate future assessment of the action of these drugs in vivo and translation into treatment could be rapid, with long term benefits to the wider public by enhancing quality of life and health. To enhance impact in this area we already have studies underway to investigate the effect of metformin on exacerbations in patients with chronic obstructive pulmonary disease. Prof. Baker also runs a patient advisory group, comprising patients and their carers who work collaboratively with researchers and clinicians to develop such projects. This group also provides advice for and a route of dissemination of results to patients. 
We are currently the only research group in the UK investigating the role of glucose homeostasis in the lung. We are leading the world in this field, which, through publication and presentation of the data at international scientific meetings, is now receiving significant attention overseas. This industrial collaboration will increase impact in this area by aiding translation and development of this novel research into therapies. The success of this project and its future development could therefore contribute to the economic competitiveness of the UK.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-03-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>364767</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ghent</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:department>Department of Pediatrics and Medical Genetics</gtr:department><gtr:description>GLUT10 KO mice</gtr:description><gtr:id>21CDBB20-D3B5-4B82-95EA-FE4CAD90068E</gtr:id><gtr:impact>Currently in process of sample collection, data acquisition and analysis.</gtr:impact><gtr:partnerContribution>The provision of GLUT10 KO mice for the analysis of airway surface liquid, isolation of airway cells and tissue.</gtr:partnerContribution><gtr:piContribution>We are providing data on the effect of GLUT10 KO on the pathophysiology of the airway. This will contribute to our understanding of the function of GLUT10 as a glucose transporter and its role in arterial tortuosity syndrome.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UNC School of Medicine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>UNC CF and Smoking centre</gtr:description><gtr:id>EEE62F57-1437-49E0-ADEC-A0E056937079</gtr:id><gtr:impact>Helassa N, Garnett JP, Farrant M, Khan F, Pickup JC, Hahn KM, MacNevin CJ, Tarran R, Baines DL. 2014 A novel fluorescent sensor protein for detecting changes in airway surface liquid glucose concentration. Biochem J. Sep 15. [Epub ahead of print] PMID: 25220254

Garnett JP, Tarran R, Gray MA, Ward C, Brodlie M, Baker EH and Baines DL (2013). Elevated glucose flux across cystic fibrosis airway epithelium is an important factor for Pseudomonas aeruginosa growth in airway epithelial co-culture. PLoS ONE 8(10): e76283. doi:10.1371/journal.pone.0076283</gtr:impact><gtr:partnerContribution>provision of primary cultures lung epithelial cells</gtr:partnerContribution><gtr:piContribution>How hyperglycaemia contributes to CF disease and effects of smoking on airway. Development of glucose sensor for use in vitro.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UNC School of Medicine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Chapel Hill Pharmacology</gtr:description><gtr:id>3B4D7399-AE31-4FA6-A1B2-8744799A0B8A</gtr:id><gtr:impact>Helassa N, Garnett JP, Farrant M, Khan F, Pickup JC, Hahn KM, MacNevin CJ, Tarran R, Baines DL. 2014 A novel fluorescent sensor protein for detecting changes in airway surface liquid glucose concentration. Biochem J. Sep 15. [Epub ahead of print] PMID: 25220254

Hyperglycaemia and Pseudomonas aeruginosa acidify cystic fibrosis airway surface liquid by elevating epithelial monocarboxylate transporter 2 dependent lactate-H+ secretion. Garnett JP, Kalsi KK, Sobotta M, Bearham J, Carr G, Powell J, Brodlie M, Ward C, Tarran R, Baines DL.
Sci Rep. 2016 Nov 29;6:37955. doi: 10.1038/srep37955. PMID:27897253</gtr:impact><gtr:partnerContribution>Provision of long wavelength fluorescent dyes</gtr:partnerContribution><gtr:piContribution>Development of fluorescent glucose sensor</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Technical University of Munich</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Glucose transporter knockout mice</gtr:description><gtr:id>9106907D-ECD5-4C7B-99F0-F128AFE4DAB1</gtr:id><gtr:impact>Currently in the process of data collection and analysis for publication.</gtr:impact><gtr:partnerContribution>The partners are contributing the KO mice to the study for sample and tissue collection.</gtr:partnerContribution><gtr:piContribution>1. We are providing information on how GLUT 2/5 and SGLT1 KO in mice affects the pathophysiology of the airway.
2. We are providing samples that we collect from the airway to a potential study investigating how glucose transport affects the formation of metabolites in these animals.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>University College London (UCL), Institute of Child Health</gtr:department><gtr:description>UCL</gtr:description><gtr:id>E5D11B6E-33B9-4424-BAC5-20B201F1692D</gtr:id><gtr:impact>10.1152/ajplung.00471.2016
Sucessful Cystic Fibrosis SRC bid and funding 2016 https://www.cysticfibrosis.org.uk/the-work-we-do/research/research-we-are-funding/strategic-research-centres/src-8-hart-gene-editing</gtr:impact><gtr:partnerContribution>Provision of primary airway epithelial cells (HBE) and transformed (HBE)</gtr:partnerContribution><gtr:piContribution>Expertise in ion transport measurement across airway cells</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Respiratory and Inflammation iMED Strategy team M?lndal</gtr:department><gtr:description>MICA award</gtr:description><gtr:id>576E97FA-29B0-4A5A-86E5-9D09B13087EB</gtr:id><gtr:impact>outputs pending</gtr:impact><gtr:partnerContribution>Collaborator in MICA award 'Evaluation of anti diabetic drugs in the treatment of respiratory disease'</gtr:partnerContribution><gtr:piContribution>Collaborator in MICA award 'Evaluation of anti diabetic drugs in the treatment of respiratory disease'</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>U3A</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>240BED43-C955-4ECA-BA8D-B9BF4C3A5B23</gtr:id><gtr:impact>70 people attended the lecture, good discussion and questions after the event

request for further speakers</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Schools visits (London)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>97D9DFBC-4794-48F7-BAA0-D604F7E53325</gtr:id><gtr:impact>30 or more 15-18 year students attend talks on CF disease (AS/A2 module subject) or research. Ususally sparks discussion and leads to work experience placements at SGUL.

Sparks discussion about research and entrance to biomedical/medical degree courses. Regularly leads to work experience placements at SGUL.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>Pre-2006,2006,2007,2008,</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Engagement Event</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>22087D28-8E2C-439F-9F0B-6EF24009AFE7</gtr:id><gtr:impact>The event was Living with Type 1 Diabetes

It sparked a lot of discussion and increased awareness about research and patient experience

There were a lot of interesting question from staff and public. The event sparked public interest in future events</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.sgul.ac.uk/news/public-events</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Princes Teaching Institute</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>50D8709A-C238-4FD7-B70B-35B05D166CEE</gtr:id><gtr:impact>Invitation to present a talk discussion on Transporters to a New Teacher Subject Day, Westminster. The purpose of the day was to provide up to date scientific information and insight to help teachers translate into classroom and enthuse students. This is now an ongoing appointment</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.princes-ti.org.uk/what-we-do/new-teacher-subject-days</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>106000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC CASE studentship</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>MRC Headoffice</gtr:fundingOrg><gtr:fundingRef>MR/L013509/1</gtr:fundingRef><gtr:id>B5970A6B-C8AD-4134-902C-9CD59D8B43C5</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>718602</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cystic Fibrosis Strategic Research Centre</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Cystic Fibrosis Trust</gtr:fundingOrg><gtr:fundingRef>SRC 006</gtr:fundingRef><gtr:id>0A67045E-062F-49D3-976C-A40F67C00FF8</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A randomised, double-blind, placebo-controlled trial of metformin in chronic obstructive pulmonary disease (COPD) exacerbations: a pilot study</gtr:description><gtr:id>F24840F1-C0AC-4D72-A40C-413387DDAB41</gtr:id><gtr:impact>This intervention strategy with metformin did not ameliorate elevations in blood glucose concentration among non-diabetic patients admitted to hospital for COPD exacerbations, and had no detectable effect on CRP or clinical outcomes.</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>Metformin treatment in COPD</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>Sponsor's R&amp;D Registration Number: 10.0086 EudraCT number: 2010-020818-28</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>development of a fluorescent glucose biosensor</gtr:description><gtr:id>14422D11-A975-4DD9-852C-55AC798D3D9B</gtr:id><gtr:impact>Potential impact for use as a tool to analyse glucose in airway, predict blood glucose, and as a research tool.

Helassa N, Garnett JP, Farrant M, Khan F, Pickup JC, Hahn KM, MacNevin CJ, Tarran R, Baines DL. 2014 A novel fluorescent sensor protein for detecting changes in airway surface liquid glucose concentration. Biochem J. Sep 15. [Epub ahead of print] PMID: 25220254</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>glucose sensor</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/970CD732-5488-44F3-86EB-53038CAC7AE7"><gtr:id>970CD732-5488-44F3-86EB-53038CAC7AE7</gtr:id><gtr:title>A novel fluorescent sensor protein for detecting changes in airway surface liquid glucose concentration.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cb01b1007c1ba3ef06afd736d6e5d21e"><gtr:id>cb01b1007c1ba3ef06afd736d6e5d21e</gtr:id><gtr:otherNames>Helassa N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A993463A-F981-41D9-96DE-BBE093B76947"><gtr:id>A993463A-F981-41D9-96DE-BBE093B76947</gtr:id><gtr:title>Elevated paracellular glucose flux across cystic fibrosis airway epithelial monolayers is an important factor for Pseudomonas aeruginosa growth.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/689b2e4c3ac43a6786b1383c2eb2ccca"><gtr:id>689b2e4c3ac43a6786b1383c2eb2ccca</gtr:id><gtr:otherNames>Garnett JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2E9DDDF4-61C0-44DC-A28D-652F811E28AC"><gtr:id>2E9DDDF4-61C0-44DC-A28D-652F811E28AC</gtr:id><gtr:title>Naringenin inhibits the growth of Dictyostelium and MDCK-derived cysts in a TRPP2 (polycystin-2)-dependent manner.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b17832ab6d6038b2bc30fd2d2f2ff047"><gtr:id>b17832ab6d6038b2bc30fd2d2f2ff047</gtr:id><gtr:otherNames>Waheed A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C0D2DF7A-314C-4449-A9E0-24330B46275D"><gtr:id>C0D2DF7A-314C-4449-A9E0-24330B46275D</gtr:id><gtr:title>Pulmonary Predictors of Incident Diabetes in Smokers.</gtr:title><gtr:parentPublicationTitle>Chronic obstructive pulmonary diseases (Miami, Fla.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0a75eb60805ddcc6d7eedfbf57ea37a7"><gtr:id>0a75eb60805ddcc6d7eedfbf57ea37a7</gtr:id><gtr:otherNames>Kinney GL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2372-952X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/461C74BC-6089-4D31-95CC-DE631E5FBB7B"><gtr:id>461C74BC-6089-4D31-95CC-DE631E5FBB7B</gtr:id><gtr:title>Dapagliflozin-lowered blood glucose reduces respiratory Pseudomonas aeruginosa infection in diabetic mice.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4dd56ee11d75a3ae5271eefd5ff06d25"><gtr:id>4dd56ee11d75a3ae5271eefd5ff06d25</gtr:id><gtr:otherNames>?strand A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EE8050C7-3843-4C9F-949E-AB083338ECC1"><gtr:id>EE8050C7-3843-4C9F-949E-AB083338ECC1</gtr:id><gtr:title>Metformin reduces airway glucose permeability and hyperglycaemia-induced Staphylococcus aureus load independently of effects on blood glucose.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/689b2e4c3ac43a6786b1383c2eb2ccca"><gtr:id>689b2e4c3ac43a6786b1383c2eb2ccca</gtr:id><gtr:otherNames>Garnett JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/66B8732D-755A-4BA0-9D15-9F16C1573A07"><gtr:id>66B8732D-755A-4BA0-9D15-9F16C1573A07</gtr:id><gtr:title>Kinases as targets for ENaC regulation.</gtr:title><gtr:parentPublicationTitle>Current molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/97d69a1f93b2664f0efc43c3c65399b1"><gtr:id>97d69a1f93b2664f0efc43c3c65399b1</gtr:id><gtr:otherNames>Baines D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1874-4672</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A9A184E9-D7F8-4131-903F-61C22080C183"><gtr:id>A9A184E9-D7F8-4131-903F-61C22080C183</gtr:id><gtr:title>Elevated paracellular glucose flux across cystic fibrosis airway epithelial monolayers is an important factor for Pseudomonas aeruginosa growth.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/689b2e4c3ac43a6786b1383c2eb2ccca"><gtr:id>689b2e4c3ac43a6786b1383c2eb2ccca</gtr:id><gtr:otherNames>Garnett JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F9979A2D-E6CD-4AEC-8D44-BA4D44C8E928"><gtr:id>F9979A2D-E6CD-4AEC-8D44-BA4D44C8E928</gtr:id><gtr:title>Valproic acid protects against haemorrhagic shock-induced signalling changes via PPAR? activation in an in vitro model.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f90dd9c0cfad0cd060edf1707eb4de81"><gtr:id>f90dd9c0cfad0cd060edf1707eb4de81</gtr:id><gtr:otherNames>Zuckermann AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8F236B0D-FDF3-42FA-AA22-0C5AD1938C7C"><gtr:id>8F236B0D-FDF3-42FA-AA22-0C5AD1938C7C</gtr:id><gtr:title>Metformin prevents the effects of Pseudomonas aeruginosa on airway epithelial tight junctions and restricts hyperglycaemia-induced bacterial growth.</gtr:title><gtr:parentPublicationTitle>Journal of cellular and molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3c4adbfb9fd4aed6c7754846c953c4ce"><gtr:id>3c4adbfb9fd4aed6c7754846c953c4ce</gtr:id><gtr:otherNames>Patkee WR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1582-1838</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/09EE741D-2979-414C-844D-19C5F38EB392"><gtr:id>09EE741D-2979-414C-844D-19C5F38EB392</gtr:id><gtr:title>The epithelial sodium channel mediates the directionality of galvanotaxis in human keratinocytes.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5dd0581bb1db4f2f2df9f33f7d192aad"><gtr:id>5dd0581bb1db4f2f2df9f33f7d192aad</gtr:id><gtr:otherNames>Yang HY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BE1654B6-6F2F-49AD-BF01-6CB63F8AE683"><gtr:id>BE1654B6-6F2F-49AD-BF01-6CB63F8AE683</gtr:id><gtr:title>Interaction between extracellular matrix molecules and microbial pathogens: evidence for the missing link in autoimmunity with rheumatoid arthritis as a disease model.</gtr:title><gtr:parentPublicationTitle>Frontiers in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b5a8cf24ff8870c8a854f719f1434fa"><gtr:id>9b5a8cf24ff8870c8a854f719f1434fa</gtr:id><gtr:otherNames>Sofat N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1664-302X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0FDD17D5-B818-40C5-B18B-52200A3F1DB3"><gtr:id>0FDD17D5-B818-40C5-B18B-52200A3F1DB3</gtr:id><gtr:title>Fructose transport-deficient Staphylococcus aureus reveals important role of epithelial glucose transporters in limiting sugar-driven bacterial growth in airway surface liquid.</gtr:title><gtr:parentPublicationTitle>Cellular and molecular life sciences : CMLS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/689b2e4c3ac43a6786b1383c2eb2ccca"><gtr:id>689b2e4c3ac43a6786b1383c2eb2ccca</gtr:id><gtr:otherNames>Garnett JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1420-682X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FC96FF1C-1FB1-47EA-B0BD-0E336EB5EA99"><gtr:id>FC96FF1C-1FB1-47EA-B0BD-0E336EB5EA99</gtr:id><gtr:title>Sweet talk: insights into the nature and importance of glucose transport in lung epithelium.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/689b2e4c3ac43a6786b1383c2eb2ccca"><gtr:id>689b2e4c3ac43a6786b1383c2eb2ccca</gtr:id><gtr:otherNames>Garnett JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AE1062C9-5EFE-4755-AB36-CF00CE92BD3E"><gtr:id>AE1062C9-5EFE-4755-AB36-CF00CE92BD3E</gtr:id><gtr:title>BMI-1 extends proliferative potential of human bronchial epithelial cells while retaining their mucociliary differentiation capacity.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Lung cellular and molecular physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8decb131b291bfded9787b236dfdd510"><gtr:id>8decb131b291bfded9787b236dfdd510</gtr:id><gtr:otherNames>Munye MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1040-0605</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1F07C71A-AACF-4C7E-A222-FB70DBC6444C"><gtr:id>1F07C71A-AACF-4C7E-A222-FB70DBC6444C</gtr:id><gtr:title>Increased airway glucose increases airway bacterial load in hyperglycaemia.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/29aae759e24b7e5c203ca6c540d70f32"><gtr:id>29aae759e24b7e5c203ca6c540d70f32</gtr:id><gtr:otherNames>Gill SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/433C5054-3DA5-495B-9064-399047B77E61"><gtr:id>433C5054-3DA5-495B-9064-399047B77E61</gtr:id><gtr:title>Metformin in severe exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1e9fff71d2ec163bf6cf73174d116a89"><gtr:id>1e9fff71d2ec163bf6cf73174d116a89</gtr:id><gtr:otherNames>Hitchings AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C46EB9DB-42EF-4B85-9BFA-02FC2B65F430"><gtr:id>C46EB9DB-42EF-4B85-9BFA-02FC2B65F430</gtr:id><gtr:title>Hyperglycaemia and Pseudomonas aeruginosa acidify cystic fibrosis airway surface liquid by elevating epithelial monocarboxylate transporter 2 dependent lactate-H(+) secretion.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/689b2e4c3ac43a6786b1383c2eb2ccca"><gtr:id>689b2e4c3ac43a6786b1383c2eb2ccca</gtr:id><gtr:otherNames>Garnett JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K012770/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>